Any current/future new fundraising through debt or equity?

The company is exploring a capital raise specifically for its Novel Drugs business. The biotech market, especially in the US, is still recovering; investors currently seek more mature clinical data before committing. Jubilant Pharmova has started clinical programs and is collecting data to reach a critical mass of clinical proof of concept. They aim to raise external funding by the end of the year at favorable terms, contingent on clinical data progress. Discussions with investors about funding conditions are ongoing, influenced by recent market transactions like Merck's acquisition of Imago B

Future growth expectations in sales/revenue/volumes?

Sustainable growth expected from key pillars: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, and CRDMO businesses. Specialty Pharma: Growth driven by increased sales in Radiopharmacies and Allergy Immunotherapy. CDMO API business: Uncertain near-term outlook due to regulatory inspection outcomes but with structural cost reduction plans underway. Generics: Transformation underway with cost optimization and brand-focused growth in India and select international markets; improving profitability expected by FY'24 but losses may persist at a lower level. Drug Discov

Future growth expectations in earnings/operating earnings/profits/EPS?

Generics business losses are expected to reduce significantly by FY'24 end, aiming for close to negative mid-single-digit losses, showing substantial improvement from current levels. Radiopharmacies business is on track for breakeven by Q4 FY'24, contingent on no further disruptions. Radiopharma, Allergy Immunotherapy, and CDMO Sterile Injectables businesses are expected to drive profitability growth in FY'24. Drug Discovery Services anticipates moderate near-term growth but aims to return to double-digit growth medium-term with stable EBITDA margins around 30%. CRDMO and Drug Discover

Jubilant PharmoQ3 FY23Pharmaceuticals & Biotechnology

Jubilant Pharmo Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹946P/E: 38.9Market Cap: ₹15.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Sustainable growth expected from key pillars: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, and CRDMO businesses.
Specialty Pharma: Growth driven by increased sales in Radiopharmacies and Allergy Immunotherapy.
CDMO API business: Uncertain near-term outlook due to regulatory inspection outcomes but with structural cost reduction plans underway.
Generics: Transformation underway with cost optimization and brand-focused growth in India and select international markets; improving profitability expected by FY'24 but losses may persist at a lower level.
Drug Discovery Services: Anticipated double-digit growth starting end of FY’23, with market demand expected to pick up after a temporary moderation.
Proprietary Novel Drugs: Clinical data maturation expected to drive partnering and potential monetization; aiming for critical data by year-end to enable external funding.
Radiopharmacies: Turnaround plan on track with break-even targeted by Q4 FY'24.
Overall, expect revenue growth from new product launches, operational efficiencies, and market share gains.

Margin guidance

Category 3

Generics business losses are expected to reduce significantly by FY'24 end, aiming for close to negative mid-single-digit losses, showing substantial improvement from current levels.
Radiopharmacies business is on track for breakeven by Q4 FY'24, contingent on no further disruptions.
Radiopharma, Allergy Immunotherapy, and CDMO Sterile Injectables businesses are expected to drive profitability growth in FY'24.
Drug Discovery Services anticipates moderate near-term growth but aims to return to double-digit growth medium-term with stable EBITDA margins around 30%.
CRDMO and Drug Discovery Services are poised for sustainable growth, backed by expanded capabilities and strong customer demand, particularly in the U.S. market.
Operating efficiencies and strategic cost optimizations, including Rs 100 Crore savings by March 2023 and additional Rs 50 Crore by H1 FY'24, will improve margins.
Novel Drugs business expects fundraising post-clinical data generation by end FY'23, enabling growth and potential capital infusion.

See what Jubilant Pharmo management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company is exploring a capital raise specifically for its Novel Drugs business.
The biotech market, especially in the US, is still recovering; investors currently seek more mature clinical data before committing.
Jubilant Pharmova has started clinical programs and is collecting data to reach a critical mass of clinical proof of concept.
They aim to raise external funding by the end of the year at favorable terms, contingent on clinical data progress.
Discussions with investors about funding conditions are ongoing, influenced by recent market transactions like Merck's acquisition of Imago Biosciences.
No explicit mention of new debt fundraising was made in the transcript.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Jubilant Pharmova. However, relevant insights can be inferred: - Drug Discovery Services: The new Chemistry and DMPK Excellence Center is fully operational with high capacity utilization, preparing to handle anticipated growth and additional demand starting from end of FY '24. - CRDMO Business: Robust midterm demand outlook especially in the U.S. with strong presence among biopharmaceutical customers; double-digit growth expected from end of this year. - Generics: Resumption of production at Roorkee facility contributes to supply continuity; facility helped supply multiple international markets. - Radiopharmacies: Turnaround plan on track aiming for break-even by Q4 FY'24, with improvements in supply normalization post earlier disruptions. - Proprietary Novel Drugs: Clinical programs ongoing, with partnering efforts in progress to unlock value and advance development. No specific numeric order book or pending order figures were disclosed during the call.

See what Jubilant Pharmo management said on order book — free account, 30 seconds.

Capex plans

Yes

- Capital expenditure excluding R&D capitalization was Rs 218 Crore for Q3 FY'23 and Rs 498 Crore for the 9 months ending Dec 31, 2022. (Page 9) - Expansion of the Drug Discovery Services facility was commissioned in September 2021 and is running at high utilization; further expansion planned to catch anticipated growth starting end of FY '24. (Page 16) - Newly commissioned DMPK capability within the greater Noida site is part of Chemistry and DMPK Excellence Center expansion to develop talent and capabilities for future growth. (Page 16) - The company is investing in quality transformation programs and plant upgradation at sites like Nanjangud and Roorkee to improve API and generics business performance. (Pages 13, 17) No explicit mention of new future strategic capital investments or major capex beyond these ongoing programs and expansions is stated.

Track Jubilant Pharmo — get its next earnings analysis in your feed

How does Jubilant Pharmo rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisJubilant Pharmo

Rev 3Mar 3

See where Jubilant Pharmo sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Jubilant Pharmo rank in Pharmaceuticals & Biotechnology?

Compare Jubilant Pharmo against every Pharmaceuticals & Biotechnology company (Q3 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Jubilant Pharmo's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Jubilant Pharmo Q3 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Jubilant Pharmo rank in Pharmaceuticals & Biotechnology?

Continue your research

What Jubilant Pharmo's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season